HK1256944A1 - 經改造的宿主細胞及其使用方法 - Google Patents
經改造的宿主細胞及其使用方法Info
- Publication number
- HK1256944A1 HK1256944A1 HK18116082.5A HK18116082A HK1256944A1 HK 1256944 A1 HK1256944 A1 HK 1256944A1 HK 18116082 A HK18116082 A HK 18116082A HK 1256944 A1 HK1256944 A1 HK 1256944A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- host cells
- engineered host
- engineered
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562217677P | 2015-09-11 | 2015-09-11 | |
PCT/US2016/050850 WO2017044672A1 (en) | 2015-09-11 | 2016-09-09 | Engineered host cells and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256944A1 true HK1256944A1 (zh) | 2019-10-04 |
Family
ID=56985684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116082.5A HK1256944A1 (zh) | 2015-09-11 | 2018-12-14 | 經改造的宿主細胞及其使用方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11898165B2 (zh) |
EP (1) | EP3347453A1 (zh) |
JP (1) | JP2018531593A (zh) |
KR (1) | KR20180043840A (zh) |
CN (1) | CN108350430A (zh) |
AU (1) | AU2016318961A1 (zh) |
CA (1) | CA2996887A1 (zh) |
HK (1) | HK1256944A1 (zh) |
MA (1) | MA44907A (zh) |
TW (1) | TW201716578A (zh) |
WO (1) | WO2017044672A1 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
CA2868439C (en) | 2012-03-28 | 2023-09-26 | Umc Utrecht Holding B.V. | Combinatorial gamma 9 delta 2 t cell receptor chain exchange |
EP3065771B1 (en) | 2013-11-04 | 2019-03-20 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
SG11201909290TA (en) * | 2017-04-07 | 2019-11-28 | Uti Lp | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
FI3615674T3 (fi) | 2017-04-28 | 2024-06-18 | Univ Colorado Regents | Menetelmiä reumatoidin artriitin hoitoon HLA-geenin RNA-ohjattua genomin muokkausta käyttämällä |
MA50084A (fr) | 2017-09-04 | 2020-07-15 | Agenus Inc | Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers |
WO2019073964A1 (ja) | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | Platinum TALENを用いたT細胞受容体の完全置換技術 |
WO2019073965A1 (ja) * | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | エフェクターT細胞(Teff)抗原受容体を用いた抗原特異的制御性T細胞(Treg)の作出技術 |
US11603565B2 (en) * | 2018-06-15 | 2023-03-14 | Roche Sequencing Solutions, Inc. | System for identification of antigens recognized by T cell receptors expressed on tumor infiltrating lymphocytes |
CN109293779A (zh) * | 2018-07-03 | 2019-02-01 | 清华大学 | 一种多聚体复合物及其制备方法 |
EP3843770A4 (en) * | 2018-08-31 | 2022-06-08 | 3T Biosciences, Inc. | RANDOMIZED PEPTIDE LIBRARIES PRESENTED BY HUMAN LEUKOCYTE ANTIGENS |
EP3808765A1 (en) | 2019-10-14 | 2021-04-21 | ETH Zurich | Cell line for tcr discovery and engineering and methods of use thereof |
AU2021297458A1 (en) * | 2020-06-25 | 2023-02-02 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
CN114437232B (zh) * | 2020-11-05 | 2023-11-24 | 中国科学院分子细胞科学卓越创新中心 | 一种细胞表面大分子定量展示系统及其制备方法和用途 |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US20240060042A1 (en) * | 2020-12-22 | 2024-02-22 | National University Of Singapore | Artificial antigen-presenting cell |
WO2022214707A1 (en) * | 2021-04-09 | 2022-10-13 | Gadeta B.V. | Cellular reporter and methods of using the same |
WO2022240916A1 (en) * | 2021-05-10 | 2022-11-17 | The Regents Of The University Of Colorado, A Body Corporate | Engineered hla alleles for treating autoimmunity |
US20240247066A1 (en) * | 2021-05-12 | 2024-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Structure based isolation of pmhc-restricted antibodies |
WO2023081733A1 (en) * | 2021-11-02 | 2023-05-11 | Washington University | Compositions and methods of treatment for cancers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1188825A1 (en) | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
EP1409646B1 (en) * | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
KR102141259B1 (ko) * | 2012-09-04 | 2020-08-05 | 셀렉티스 | 멀티―체인 키메라 항원 수용체 및 그것의 용도들 |
ES2736052T3 (es) * | 2013-02-20 | 2019-12-23 | Regeneron Pharma | Ratones que expresan co-receptores humanizados de células T |
-
0
- MA MA044907A patent/MA44907A/fr unknown
-
2016
- 2016-09-09 JP JP2018512912A patent/JP2018531593A/ja not_active Withdrawn
- 2016-09-09 TW TW105129380A patent/TW201716578A/zh unknown
- 2016-09-09 WO PCT/US2016/050850 patent/WO2017044672A1/en active Application Filing
- 2016-09-09 US US15/759,007 patent/US11898165B2/en active Active
- 2016-09-09 KR KR1020187010146A patent/KR20180043840A/ko unknown
- 2016-09-09 CN CN201680064904.8A patent/CN108350430A/zh active Pending
- 2016-09-09 CA CA2996887A patent/CA2996887A1/en not_active Abandoned
- 2016-09-09 AU AU2016318961A patent/AU2016318961A1/en not_active Abandoned
- 2016-09-09 EP EP16770406.3A patent/EP3347453A1/en not_active Withdrawn
-
2018
- 2018-12-14 HK HK18116082.5A patent/HK1256944A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016318961A1 (en) | 2018-03-22 |
CA2996887A1 (en) | 2017-03-16 |
US20200263133A1 (en) | 2020-08-20 |
CN108350430A (zh) | 2018-07-31 |
MA44907A (fr) | 2018-07-18 |
EP3347453A1 (en) | 2018-07-18 |
WO2017044672A1 (en) | 2017-03-16 |
TW201716578A (zh) | 2017-05-16 |
JP2018531593A (ja) | 2018-11-01 |
KR20180043840A (ko) | 2018-04-30 |
US11898165B2 (en) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256944A1 (zh) | 經改造的宿主細胞及其使用方法 | |
IL286316A (en) | New micro-dystrophins and related method of use | |
HK1256380A1 (zh) | 修飾的細胞和治療方法 | |
HK1247238B (zh) | 改造的crispr-cas9組合物和使用方法 | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
HK1254830A1 (zh) | 工程化植酸酶及其使用方法 | |
IL282572B (en) | Tetrahydropyranylamino-pyrrolopyrimidinone and methods of using it | |
SG11201608238TA (en) | Surface energy modified particles, method of making, and use thereof | |
SI3131577T1 (sl) | Modificirane gostiljske celice in uporabe le-teh | |
IL251885A0 (en) | Noscapinoid-Producing Bacteria and Methods for Their Preparation and Use | |
SG11201504771RA (en) | Host cells and methods of use | |
IL254783A0 (en) | Combinations for deworming methods for using them | |
ZA201604870B (en) | Recombinant microorganisms and methods of use thereof | |
HK1243105A1 (zh) | 高活性的腫瘤抑制劑及其製法和應用 | |
EP3137873A4 (en) | Viscometer and methods of use thereof | |
GB201403107D0 (en) | Permeability and transformation of cells | |
IL247448A0 (en) | Peptides and methods of use | |
GB201622225D0 (en) | Modified host cells and uses thereof | |
GB201416797D0 (en) | Contianer and method of use thereof | |
AU2014901577A0 (en) | Thermo-Electrochemical Cell and Method of Use |